D. Denis

发表

1-YEAR CONTROLLED RANDOMISED TRIAL OF PREVENTION OF EARLY POSTMENOPAUSAL BONE LOSS BY INTRANASAL CALCITONIN

J. Reginster, P. Franchimont, M. Lecart, 1987, The Lancet.

Long‐term (3 years) prevention of trabecular postmenopausal bone loss with low‐dose intermittent nasal salmon calcitonin

J. Reginster, P. Franchimont, M. de Longueville, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE

J. Reginster, P. Franchimont, J. Collette, 1989, The Lancet.

In vivo long-term precision of spinal bone mass measurement by dual photon absorptiometry.

P. Geusens, J. Reginster, J. Dequeker, 1989, Bone and mineral.

Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone.

J. Reginster, P. Franchimont, C. Gennari, 1990, Scandinavian journal of rheumatology.

Acute biochemical variations induced by four different calcium salts in healthy male volunteers

J. Reginster, P. Franchimont, B. Zegels, 1993, Osteoporosis International.

One year's treatment of paget's disease of bone by synthetic salmon calcitonin as a nasal spray

J. Reginster, P. Franchimont, J. Reginster, 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Influence of the nature of calcium salts on serum calcium, phosphorus, calcitonin, growth hormone, and somatomedin C

J. Reginster, P. Franchimont, G. Heynen, 1988, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

Dual photon absorptiometry of lumbar spine in West European (Belgian) postmenopausal females: normal range and fracture threshold

J. Reginster, P. Franchimont, J. Collette, 1990, Clinical Rheumatology.

Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects.

J. Reginster, P. Franchimont, A. Albert, 1987, Bone and mineral.

Is there any place for salmon calcitonin in prevention of postmenopausal bone loss?

J. Reginster, P. Franchimont, M. Lecart, 1988, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics.

J. Reginster, P. Franchimont, J. Collette, 1989, The Journal of clinical investigation.

Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone.

J. Reginster, P. Franchimont, J. Collette, 1988, Bone.

In vivo anti-inflammatory activity of grandiflorenic acid and kaurenic acid isolated from Coespeletia moritziana and Espeletia semiglobulata

M. Dubois, A. Usubillaga, Philippe A. Peixoto, 2017 .

[Preoperative and postoperative measurement of carcinoembryonic antigen (CEA): a prognostic factor in surgically treated rectocolic neoplasms?].

J. Reginster, P. Franchimont, C. Desaive, 1985, Revue Medicale de Liege.

Prevention of early postmenopausal bone loss by intranasal calcitonin - a controlled, randomised study lasting one year in normal women

J. Reginster, P. Franchimont, R. Deroisy, 1988 .